Shelley Braham

Canada

PAPER Brotherton TE, Li Y, Cooper D, Gearing M, Julien JP, Rothstein JD, Boylan K, Glass JD

Localization of a toxic form of superoxide dismutase 1 protein to pathologically affected tissues in familial ALS.

Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5505-10. PubMed: 22431618

C4F6 Targets Protein That Sinks Motor Neurons

RESEARCH NEWS 2012-03-27 Research News No, this isn’t about the board game "Battleship." C4F6 is an antibody to a mutant form of superoxide dismutase 1 (SOD1). In people with a rare form of amyotrophic lateral sclerosis, every cell produces mutant SOD1, but only certain

Kate Bristow

University of Washington
United States

Velina Sevdalinova

Boston, United States

Ed Thomas

Consultant
United States

Sarjan Khalaf

Venezuela, Bolivarian Republic of

Hollie Schmidt

United States

Hermes Bgas

United States

PAPER Pearson CA

Thiacetazone toxicity in the treatment of tuberculosis patients in Nigeria.

J Trop Med Hyg. 1978 Dec 1;81(12):238-42. PubMed: 85717

AD in the Oldest Old—What Does Aβ Have to Do With It?

WEBINAR 2012-03-26 In a keynote lecture at the Human Amyloid Imaging conference, held 12-13 January 2012 in Miami, Florida, Claudia Kawas argued that the oldest old should receive more attention. Kawas leads the world’s largest study of people 90 and older. Listen to the ke

Sanjay Pimplikar on Antioxidants No Help for Alzheimer’s, Biomarker Trial Says

COMMENT These conclusions are based on a four-month treatment, whereas most trials go on for 18 months, and some even for 36 months. Knowing the complexity of AD pathogenesis, would a four-month treatment be considered sufficiently long to test the efficacy of an

Vernon Eden

Mexico

PAPER Trell E, Korsgaard R, Hood B, Kitzing P, Nordén G, Simonsson BG

Letter: Aryl hydrocarbon hydroxylase inducibility and laryngeal carcinomas.

Lancet. 1976 Jul 17;2(7977):140. PubMed: 59196

Malgorzata Matlach

Vierbheim, Germany